In tissue diagnostics, the value is built across a chain of unglamorous steps: a sample is removed, fixed, embedded, sliced, stained, scanned, and finally read — by a pathologist or, increasingly, by software. The companies that supply that workflow tend to file across the whole chain rather than on any single instrument, because coverage on one step is worth more when it connects to the next. The first week of April 2026 produced a grant that illustrates how Ventana Medical Systems, the tissue-diagnostics arm of Roche, builds that kind of footprint.

On 7 April 2026, the U.S. patent office granted US12594551B2, "Transporter systems, assemblies and associated methods for transporting tissue samples." The claimed device addresses a step that happens before any test runs — getting a removed tissue sample properly fixed while it travels to the lab. The abstract describes the mechanism directly:

In one embodiment, the disclosed assembly includes a transport container, a fixative in the transport container, and a cooling device that reduces and/or maintains the temperature of the fixative to perform a pre-soaking process at a temperature of less than about 7° C.— Transporter systems, assemblies and associated methods for transporting tissue samples, US12594551B2

The grant's CPC classifications sit in the laboratory-handling and sample-preparation classes — B01L 3/502 and B01L 9/06 for the container and carrier hardware, G01N 1/31 for specimen fixation — which places it squarely in the pre-analytic, sample-handling end of the pipeline rather than in chemistry or therapeutics. The claims reach to the practical detail of the container, including that each cavity is "sized to include the histology cassette," the standard format every downstream stainer and scanner expects. For a business reader, the point is not the cooling mechanism itself but where it sits: coverage on the first physical step of a workflow whose later steps Ventana also supplies.

The grant sits inside a tissue-to-image estate

What makes this a coverage map is the footprint around it. Ventana's issued patents extend across the instruments that act on a sample after it arrives. On the staining side, US10495654B2 covers thermal management during automated histological staining, and US10416176B2 covers the staining reagents and liquids dispensed in that automated process — coverage on both the machine and the consumables it runs. On the imaging side, US10462322B2 covers an image-scanning apparatus for digitizing slides, and US10317661B2 covers an automated coverslipper — the step that prepares a slide for scanning.

The estate then reaches into the software that reads the resulting images, which is where the most recent filing activity concentrates. US12645996B2 covers an active-learning system for digital pathology, classified in the machine-learning class G06N 20/00, and US10489904B2 covers a machine-learning classifier for assessing breast-cancer recurrence risk from slide images. Sample transport, automated staining, reagents, slide scanning, coverslipping, and image-analysis algorithms: the issued footprint reads as layered coverage across the full tissue-to-image pipeline, with the new transport grant adding the upstream tile.

The volume behind that footprint is itself a data point. Ventana's grant count in the public patent record runs into the hundreds, with the CPC distribution heavily weighted toward G06T image-processing classes (G06T 7/0012, G06T 2207/30024) and G01N sample-handling classes (G01N 1/312, G01N 35/00029) — the two ends of the workflow, hardware and software. Annual issued-grant counts in the index sit in the 30-to-50 range across recent years, indicating a program that converts filings into issued coverage on a steady cadence rather than in one-off bursts. Reading the CPC mix, the direction is consistent: the older grants cluster on the physical instruments, and the newest ones — the active-learning and risk-classification patents — point toward the image-analysis and machine-learning layer.

It is worth being concrete about why a diagnostics supplier files this way. A single immunohistochemistry or in-situ result depends on every prior step having been done to spec — a sample fixed at the right temperature, sliced and mounted in a standard cassette, stained on a calibrated instrument, then scanned at a resolution the analysis software can use. Each step is a distinct engineering problem and separately patentable, which is why one diagnostic test can sit behind dozens of device and software grants spanning the whole pipeline. The April transport patent is the earliest such step — preserving the sample before any test begins — captured as its own claim, and it is the integration across steps, not any single instrument, that gives the estate its weight.

What the issued coverage buys

The business significance of a coverage map like this is in freedom-to-operate across an integrated workflow. A granted claim is the enforceable part of an estate, and Ventana's grants are distributed along a chain where the steps depend on one another — a sample handled in a particular container format flows into stainers and scanners built for that format. A competitor entering one step of tissue diagnostics has to navigate issued claims that occupy the adjacent steps, which is the kind of pressure that surfaces as design-arounds, licensing, or supplier lock-in rather than in any single headline. The 7 April 2026 transport grant shows the company still issuing coverage at the very front of that chain, even as its newest filings move toward the software at the back.

The usual caveats apply to a coverage read. Issued claims describe what was granted, not how broadly a court would construe them or whether any survives a validity challenge, and the older instrument grants reflect filings made years ago whose terms run on their own clocks. Tissue diagnostics also has other large suppliers filing comparable hardware and imaging patents, so this footprint maps one company's positions rather than the whole field. But the pattern across Ventana's issued patents is coherent: coverage concentrated on each link of the tissue-to-image pipeline — transport, staining, reagents, scanning, and analysis — under a single corporate parent. The April grant is the newest tile in that map, and it sits on the step that comes before everything else.